|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yazici O, Sendur MA, Ozdemir N and Aksoy
S: Targeted therapies in gastric cancer and future perspectives.
World J Gastroenterol. 22:471–489. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wong SS, Kim KM, Ting JC, Yu K, Fu J, Liu
S, Cristescu R, Nebozhyn M, Gong L, Yue YG, et al: Genomic
landscape and genetic heterogeneity in gastric adenocarcinoma
revealed by whole-genome sequencing. Nat Commun. 5:54772014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee J and Kim KM: Biomarkers for gastric
cancer: Molecular classification revisited. Precis Future Med.
1:59–68. 2017. View Article : Google Scholar
|
|
5
|
Setia N, Agoston AT, Han HS, Mullen JT,
Duda DG, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A,
Lennerz JK, et al: A protein and mRNA expression-based
classification of gastric cancer. Mod Pathol. 29:772–784. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fashoyin-Aje L, Donoghue M, Chen H, He K,
Veeraraghavan J, Goldberg KB, Keegan P, McKee AE and Pazdur R: FDA
Approval Summary: Pembrolizumab for Recurrent Locally Advanced or
Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Expressing PD-L1. Oncologist. 24:103–109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kulangara K, Zhang N, Corigliano E,
Guerrero L, Waldroup S, Jaiswal D, Ms MJ, Shah S, Hanks D, Wang J,
et al: Clinical Utility of the Combined Positive Score for
Programmed Death Ligand-1 Expression and the Approval of
Pembrolizumab for Treatment of Gastric Cancer. Arch Pathol Lab Med.
143:330–337. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nishimura H and Honjo T: PD-1: An
inhibitory immunoreceptor involved in peripheral tolerance. Trends
Immunol. 22:265–268. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Boussiotis VA: Molecular and biochemical
aspects of the PD-1 checkpoint pathway. N Engl J Med.
375:1767–1778. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fanoni D, Tavecchio S, Recalcati S, Balice
Y, Venegoni L, Fiorani R, Crosti C and Berti E: New monoclonal
antibodies against B-cell antigens: Possible new strategies for
diagnosis of primary cutaneous B-cell lymphomas. Immunol Lett.
134:157–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Terme M, Ullrich E, Aymeric L, Meinhardt
K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G,
et al: IL-18 induces PD-1-dependent immunosuppression in cancer.
Cancer Res. 71:5393–5399. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hino R, Kabashima K, Kato Y, Yagi H,
Nakamura M, Honjo T, Okazaki T and Tokura Y: Tumor cell expression
of programmed cell death-1 ligand 1 is a prognostic factor for
malignant melanoma. Cancer. 116:1757–1766. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sui H, Ma N, Wang Y, Li H, Liu X, Su Y and
Yang J: Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer:
Toward Personalized Medicine and Combination Strategies. J Immunol
Res. 2018:69849482018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Llosa NJ, Cruise M, Tam A, Wicks EC,
Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS,
et al: The vigorous immune microenvironment of microsatellite
instable colon cancer is balanced by multiple counter-inhibitory
checkpoints. Cancer Discov. 5:43–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiao Y and Freeman GJ: The microsatellite
instable subset of colorectal cancer is a particularly good
candidate for checkpoint blockade immunotherapy. Cancer Discov.
5:16–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Caruso ML: Role of mismatch repair
proteins and microsatellite instability in colon carcinoma.
Immunohistochemistry and in situ hybridization of human carcinomas.
Hayat MA: Elsevier Academic Press; New York, NY: pp. 215–226.
2005
|
|
18
|
Bass AJ, Thorsson V, Shmulevich I,
Reynolds SM, Miller M, Bernard B, Hinoue T, Laird PW, Curtis C,
Shen H, et al Cancer Genome Atlas Research Network, : Comprehensive
molecular characterization of gastric adenocarcinoma. Nature.
513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Burke AP, Yen TS, Shekitka KM and Sobin
LH: Lymphoepithelial carcinoma of the stomach with Epstein-Barr
virus demonstrated by polymerase chain reaction. Mod Pathol.
3:377–380. 1990.PubMed/NCBI
|
|
20
|
Tie Y, Ma X, Zhu C, Mao Y, Shen K, Wei X,
Chen Y and Zheng H: Safety and efficacy of nivolumab in the
treatment of cancers: A meta-analysis of 27 prospective clinical
trials. Int J Cancer. 140:948–958. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim KJ, Yang HK, Kim WH and Kang GH:
Combined prognostic effect of PD-L1 expression and immunoscore in
microsatellite-unstable advanced gastric cancers. Oncotarget.
8:58887–58902. 2017.PubMed/NCBI
|
|
22
|
Li Z, Lai Y, Sun L, Zhang X, Liu R, Feng
G, Zhou L, Jia L, Huang X, Kang Q, et al: PD-L1 expression is
associated with massive lymphocyte infiltration and histology in
gastric cancer. Hum Pathol. 55:182–189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Valentini AM, Di Pinto F, Cariola F,
Guerra V, Giannelli G, Caruso ML and Pirrelli M: PD-L1 expression
in colorectal cancer defines three subsets of tumor immune
microenvironments. Oncotarget. 9:8584–8596. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Taube JM1, Anders RA, Young GD, Xu H,
Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL
and Chen L: Colocalization of inflammatory response with B7-h1
expression in human melanocytic lesions supports an adaptive
resistance mechanism of immune escape. Sci Transl Med.
4:127ra372012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Teng MWL, Ngiow SF, Ribas A and Smyth MJ:
Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer
Res. 75:2139–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koh J, Ock CY, Kim JW, Nam SK, Kwak Y, Yun
S, Ahn SH, Park DJ, Kim HH, Kim WH, et al: Clinicopathologic
implications of immune classification by PD-L1 expression and
CD8-positive tumor-infiltrating lymphocytes in stage II and III
gastric cancer patients. Oncotarget. 8:26356–26367. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma J, Li J, Hao Y, Nie Y, Li Z, Qian M,
Liang Q, Yu J, Zeng M and Wu K: Differentiated tumor immune
microenvironment of Epstein-Barr virus-associated and negative
gastric cancer: Implication in prognosis and immunotherapy.
Oncotarget. 8:67094–67103. 2017.PubMed/NCBI
|
|
28
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Feldman AT and Wolfe D: Tissue processing
and hematoxylin and eosin staining. Methods Mol Biol. 1180:31–43.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ju X, Shen R, Huang P, Zhai J, Qian X,
Wang Q and Chen M: Predictive relevance of PD-L1 expression with
pre-existing TILs in gastric cancer. Oncotarget. 8:99372–99381.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang W, Wang K, Chen Z, Chen L, Guo W,
Liao P, Rotroff D, Knepper TC, Liu Z, Zhang W, et al:
Immunoclassification characterized by CD8 and PD-L1 expression is
associated with the clinical outcome of gastric cancer patients.
Oncotarget. 9:12164–12173. 2018.PubMed/NCBI
|
|
32
|
Hofmann M, Stoss O, Shi D, Büttner R, van
de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment
of a HER2 scoring system for gastric cancer: Results from a
validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bartley AN, Washington MK, Colasacco C,
Ventura CB, Ismaila N, Benson AB III, Carrato A, Gulley ML, Jain D,
Kakar S, et al: HER2 Testing and Clinical Decision Making in
Gastroesophageal Adenocarcinoma: Guideline From the College of
American Pathologists, American Society for Clinical Pathology, and
the American Society of Clinical Oncology. J Clin Oncol.
35:446–464. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim
TM, Jeon YK, Kim DW, Chung DH and Heo DS: Pan-Cancer Immunogenomic
Perspective on the Tumor Microenvironment Based on PD-L1 and CD8
T-Cell Infiltration. Clin Cancer Res. 22:2261–2270. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Böger C, Behrens HM, Mathiak M, Krüger S,
Kalthoff H and Röcken C: PD-L1 is an independent prognostic
predictor in gastric cancer of Western patients. Oncotarget.
7:24269–24283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang L, Zhang Q, Ni S, Tan C, Cai X, Huang
D and Sheng W: Programmed death-ligand 1 expression in gastric
cancer: Correlation with mismatch repair deficiency and
HER2-negative status. Cancer Med. 7:2612–2620. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T,
Wang Q and Jiang J: PD-1 and PD-L1 co-expression predicts favorable
prognosis in gastric cancer. Oncotarget. 8:64066–64082.
2017.PubMed/NCBI
|
|
38
|
Harada K, Dong X, Estrella JS, Correa AM,
Xu Y, Hofstetter WL, Sudo K, Onodera H, Suzuki K, Suzuki A, et al:
Tumor-associated macrophage infiltration is highly associated with
PD-L1 expression in gastric adenocarcinoma. Gastric Cancer.
21:31–40. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T,
Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al: Safety and
Efficacy of Pembrolizumab Monotherapy in Patients With Previously
Treated Advanced Gastric and Gastroesophageal Junction Cancer:
Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 4:e1800132018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Apicella M, Corso S and Giordano S:
Targeted therapies for gastric cancer: Failures and hopes from
clinical trials. Oncotarget. 8:57654–57669. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fang W, Chen Y, Sheng J, Zhou T, Zhang Y,
Zhan J, Liu L, Huang J, Peng P and Zhang L: Association between
PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall
Survival in Patients with Gastric Cancer. J Cancer. 8:1579–1585.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ying L, Yan F, Meng Q, Yuan X, Yu L,
Williams BRG, Chan DW, Shi L, Tu Y, Ni P, et al: Understanding
immune phenotypes in human gastric disease tissues by multiplexed
immunohistochemistry. J Transl Med. 15:2062017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cavalcanti E, Armentano R, Valentini AM,
Chieppa M and Caruso ML: Role of PD-L1 expression as a biomarker
for GEP neuroendocrine neoplasm grading. Cell Death Dis.
8:e30042017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Saltz LB, Meropol NJ, Loehrer PJ Sr,
Needle MN, Kopit J and Mayer RJ: Phase II trial of cetuximab in
patients with refractory colorectal cancer that expresses the
epidermal growth factor receptor. J Clin Oncol. 22:1201–1208. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan
J, Zhong X, Li X, Qian H and Wang X: PD-L1 and gastric cancer
prognosis: A systematic review and meta-analysis. PLoS One.
12:e01826922017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kawazoe A, Kuwata T, Kuboki Y, Shitara K,
Nagatsuma AK, Aizawa M, Yoshino T, Doi T, Ohtsu A and Ochiai A:
Clinicopathological features of programmed death ligand 1
expression with tumor-infiltrating lymphocyte, mismatch repair, and
Epstein-Barr virus status in a large cohort of gastric cancer
patients. Gastric Cancer. 20:407–415. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Udall M, Rizzo M, Kenny J, Doherty J, Dahm
S, Robbins P and Faulkner E: PD-L1 diagnostic tests: A systematic
literature review of scoring algorithms and test-validation
metrics. Diagn Pathol. 13:122018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik
JH, Kim YA, Kim TM, Heo DS, Kim CW, et al: Clinicopathological
analysis of programmed cell death 1 and programmed cell death
ligand 1 expression in the tumour microenvironments of diffuse
large B cell lymphomas. Histopathology. 68:1079–1089. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Scognamiglio G, De Chiara A, Di Bonito M,
Tatangelo F, Losito NS, Anniciello A, De Cecio R, D'Alterio C,
Scala S, Cantile M, et al: Variability in Immunohistochemical
Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue
Types. Int J Mol Sci. 17:E7902016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Romano E and Romero P: The therapeutic
promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer:
Unleashing the CD8 T cell mediated anti-tumor activity results in
significant, unprecedented clinical efficacy in various solid
tumors. J Immunother Cancer. 3:152015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Grabsch HI and Tan P: Gastric cancer
pathology and underlying molecular mechanisms. Dig Surg.
30:150–158. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jiang Y, Zhang Q, Hu Y, Li T, Yu J, Zhao
L, Ye G, Deng H, Mou T, Cai S, et al: ImmunoScore Signature: A
Prognostic and Predictive Tool in Gastric Cancer. Ann Surg.
267:504–513. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Choi YY, Bae JM, An JY, Kwon IG, Cho I,
Shin HB, Eiji T, Aburahmah M, Kim HI, Cheong JH, et al: Is
microsatellite instability a prognostic marker in gastric cancer? A
systematic review with meta-analysis. J Surg Oncol. 110:129–135.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Shinozaki-Ushiku A, Kunita A and Fukayama
M: Update on Epstein-Barr virus and gastric cancer (review). Int J
Oncol. 46:1421–1434. 2015.(review). View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Niedobitek G, Young LS, Sam CK, Brooks L,
Prasad U and Rickinson AB: Expression of Epstein-Barr virus genes
and of lymphocyte activation molecules in undifferentiated
nasopharyngeal carcinomas. Am J Pathol. 140:879–887.
1992.PubMed/NCBI
|
|
57
|
Wang F, Flanagan J, Su N, Wang LC, Bui S,
Nielson A, Wu X, Vo HT, Ma XJ and Luo Y: RNAscope: A novel in situ
RNA analysis platform for formalin-fixed, paraffin-embedded
tissues. J Mol Diagn. 14:22–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Nishikawa J, Iizasa H, Yoshiyama H,
Shimokuri K, Kobayashi Y, Sasaki S, Nakamura M, Yanai H, Sakai K,
Suehiro Y, et al: Clinical Importance of Epstein-Barr
Virus-Associated Gastric Cancer. Cancers (Basel). 10(pii):
E1672018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan
X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA:
Association of PD-1, PD-1 ligands, and other features of the tumor
immune microenvironment with response to anti-PD-1 therapy. Clin
Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Oki E, Okano S, Saeki H, Umemoto Y,
Teraishi K, Nakaji Y, Ando K, Zaitsu Y, Yamashita N, Sugiyama M, et
al: Protein Expression of Programmed Death 1 Ligand 1 and HER2 in
Gastric Carcinoma. Oncology. 93:387–394. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Gonzalez RS, Messing S, Tu X, McMahon LA
and Whitney-Miller CL: Immunohistochemistry as a surrogate for
molecular subtyping of gastric adenocarcinoma. Hum Pathol.
56:16–21. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Eto S, Yoshikawa K, Nishi M, Higashijima
J, Tokunaga T, Nakao T, Kashihara H, Takasu C, Iwata T and Shimada
M: Programmed cell death protein 1 expression is an independent
prognostic factor in gastric cancer after curative resection.
Gastric Cancer. 19:466–471. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zhang L, Qiu M, Jin Y, Ji J, Li B, Wang X,
Yan S, Xu R and Yang D: Programmed cell death ligand 1 (PD-L1)
expression on gastric cancer and its relationship with
clinicopathologic factors. Int J Clin Exp Pathol. 8:11084–11091.
2015.PubMed/NCBI
|
|
65
|
Ohman U, Wetterfors J and Moberg A:
Histologic grading of gastric cancer. Acta Chir Scand. 138:384–390.
1972.PubMed/NCBI
|
